Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, Bertolini F, Finocchiaro G, Eoli M.
Cuppini L, et al. Among authors: calleri a.
PLoS One. 2013 Sep 12;8(9):e74345. doi: 10.1371/journal.pone.0074345. eCollection 2013.
PLoS One. 2013.
PMID: 24069296
Free PMC article.